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Abstract
Background: Pseudomonas aeruginosa is a pathogenic organism res-
ponsible for frequent wound and nosocomial infections worldwide. 
Its infections are difficult to control since the organism is known to 
rapidly develop antibiotic resistance and becomes multidrug-resistant 
(MDR) during treatment of patients. 
Aim of the study: This study was intended to investigate the oc-
currence of certain important types of (ESBL) and (MBL) enzymes in 
association with important specific virulence factors associated with 
P. aeruginosa clinical isolates from Khartoum, Sudan.
Methods: This study investigated 70 P. aeruginosa isolates which were 
collected from patients admitted to four major hospitals in Khartoum 
(Fedail, Ribat, Ibn Sina and Soba hospitals). These isolates were reco-
vered from 40 wound swabs (57.1%), 27 urine samples (38.6%), and 
3 pleural fluid samples (4.3%) of patients. Higher numbers of isolates 
were recovered from males 42 (60%) than in females 28 (40%). All P. 
aeruginosa isolates were first confirmed by conventional biochemical 
and second using molecular PCR tests. PCR methods were also used 
for detecting the presence of the virulence genes ToxA, AlgD, LasB, 
exoS, exoU, CTX, GES-1, and genes of VIM, IMP, KPC, CTX, VEB-1 
and SHV-1. 
Results: Antimicrobial susceptibility testing of P. aeruginosa isolates 
showed a high resistance to azetronam 49 (70%), followed by cefta-
zidime 32 (45.7%), 16 ciprofloxacin (22.9%), gentamicin 13 (18.6%), 
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Introduction 
Pseudomonas aeruginosa is an opportunistic patho-
gen. The organism is frequently causes nosocomial 
infection, wound sepsis, pneumonia and urinary 
tract infections (UTIs) in hospitalized patients, espe-
cially in intensive care units (ICUs) [1-5].
P. aeruginosa needs very limited nutritional requi-
rements. It can survive in distilled water [6]. The or-
ganism survives at wide range of temperature (4-42 
°C), and it is also tolerant to disinfectants and high 
concentrations of salts [7]. P. aeruginosa is capable 
of producing several different pigments, which are 
pyocyanin (blue), pyoverdin (yellow and fluorescent), 
pyorubin (red), and pyomelanin (brown) [8]. 
Multidrug-resistant P. aeruginosa is considered 
to be a serious problem in all types of infections 
because the organism has intrinsic resistance to se-
veral drug classes and it is able to acquire resistance 
to most normally effective anti-Pseudomonal drugs 
within a short period [9]. 
There are many virulence factors that may con-
tribute to pathogenic potential of P. aeruginosa, 
such as elastase, alkaline protease hemolysins 
(phospholipase and lecithinase) and pyocyanin 
diffusible pigment. In addition, most P. aeruginosa 
strains produce a variety of toxins especially exoto-
xin encoded by the toxA gene, which inhibits pro-
tein biosynthesis and is responsible for tissue ne-
crosis. Exoenzyme S is encoded by the exoS gene, 
which is secreted by a type-III secretion system 
directly into the cytosol of host epithelial cells and 
subsequently causes their destruction [10]. Other 
important virulence factor found in P. aeruginosa 
include algD, which codes for GDP mannose de-
hydrogenase, which is transcriptionally activated in 
mucoid strains, and elastase B, a zinc metallopro-
piperacillin-tazobactam 11 (15.7%), amikacin 9 (12.9%), and imipenem 
6 (8.6%) showed the least resistance. All isolates were positive for algD 
and lasB (100%), followed by toxA (90%), exoS (34.3), exoU (24.3%), 
respectively. The rates of detected ESBL genes blaTEM, blaCTX-m, 
blaSHV-1,GES-1, were 3.3%, 6.6%, 10%, 3.3%, 10%, respectively, 
but all isolates were negative for bla-KPC and bla- VIM and IMP . The 
percentages of pigment production were 61.4% for pyocyanin, 37.1% 
for pyoverdin and 1.4% for pyorubin. 
Conclusion: The study demonstrated high rates of antimicrobial re-
sistance markers to most commonly used antibiotics in treatment of 
P. aeruginosa infections. The majority of the isolates from urine and 
wound samples carried at least three potential virulence factor genes 
of algD, lasB and toxA and without any significant relation to their 
antimicrobial resistance markers. 
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tease encoded by the (lasB) gene, which attacks 
eukaryotic cells [11-12]. P. aeruginosa may also pos-
sess flagellae and pili, which helps in motility and 
adherence to host cells [13]. 
In recent years, a new variety of β-lactamases 
have been detected in P. aeruginosa clinical isola-
tes. Broad spectrum β-lactam resistance attributed 
to β-lactamases is generally due to the metallo-β-
lactamases (MBLs) such as IMP and VIM. The over 
expression of chromosomally encoded cephalospo-
rinase, AmpC, is prevalent in P. aeruginosa. These 
MBLs hydrolyze anti-Pseudomonal cephalosporins 
and carbapenems effectively and their activity is not 
suppressed by the β-lactamase inhibitors that are 
currently available for treatment [14-15]. 
This study aimed to investigate P. aeruginosa 
isolates obtained from various clinical specimens of 
patients in Khartoum, Sudan, for their antimicrobial 
resistance profile, the occurrence of most important 
MBL genes and the common specific virulence fac-
tors using PCR molecular and culture tests. 
Materials and Methods 
This study included a total of 70 different clinical P. 
aeruginosa isolates collected from patients admit-
ted to four hospitals in Khartoum, Sudan, during 
the period between September to November 2017. 
All patients were on treatment with various anti-
biotics. 
The data about each patient was obtained and 
registered as the following: name, gender, age, and 
type of specimen, and all patients are agreed for 
any necessary medical process once they are admit-
ted to each hospital. 
Culture and isolation
All P. aeruginosa isolates were preserved in cryo tu-
bes containing brain heart infusion with 15% glyce-
rol samples and transported from Sudan to Jordan. 
All isolates were then subcultured on Pseudomonas 
Agar plates and incubated for 24 to 48 hours at 37 
°C, and were examined for the presence of pigmen-
tation and grape-like odor of P. aeruginosa at the 
research laboratories of the School of Medicine, The 
University of Jordan, Amman, Jordan. 
Identification and storage 
All growth of P. aeruginosa isolates was first identi-
fied using conventional biochemical tests including 
oxidase test, develop pigmention and growth on 42 
°C and produce no chemical reaction during culture 
in Kligler's iron agar tube were stored in cryo tubes 
at -70°C. 
Antimicrobial susceptibility using disc 
diffusion method 
Antimicrobial susceptibility using disc diffusion test 
was performed according to the guidelines of the 
Clinical Laboratory and Standards Institute (CLSI, 
2016) [16].
Minimum inhibitory concentration (MIC) 
using E-test
This test was only performed on the P. aeruginosa 
isolates, which were MDR to three or more antibio-
tic classes. Four classes of antibiotics were tested 
(ceftazidime, ciprofloxacin, imipenem and amika-
cin). Results were interpreted according to the CLSI 
2016 guidelines [16].
DNA extraction and PCR 
The DNA extraction was performed according to 
the Promega kit (USA). Two PCR assays were per-
formed to confirm the isolates; one is specific for 
the genus Pseudomonas, while the other is specific 
for P. aeruginosa. Two pairs of primers were used 
for each assay based on 16S ribosomal DNA (rDNA) 
sequence as shown in Table 1.
The bacterial plasmid of freshly cultured P. aeru-
ginosa isolates was extracted according to manu-
facturer instructions using the Zyppy TM Plasmid 
Miniprep Kit (QIAGEN, Germantown, MD, USA)for 
detection of ESBLs, MBLs and virulence genes. All 
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Table 1.  16S rDNA primers sets for differentiation of P. aeruginosa from Pseudomonas species and their 
sequences and product size.
Target Primer Primer sequence (5' to 3') Product size(bp) Reference
Pseudomonas species PA-GS-F
PA-GS-R
 GACGGGTGAGTAATGCCTA 
 CACTGGTGTTCCTTCCTATA 
618 17
P. aeruginosa
PA-SS-F
PA-SS-R
 GGGGGATCTTCGGACCTCA 
 TCCTTAGAGTGCCCACCCG- 
956 17
Table 2. Primer targets, sequences and their product size for five ESBLs and virulence genes.
Target Primer Primer sequence (5' to 3') Product size (bp) Reference 
blaCTX-M CTX-M(F)
CTX-M(R)
 CGCTTTGCGATGTGCAG 
 ACCGCGATATCGTTGGT 
550 18
blaTEM
TEM-A
TEM-B
 ATAAAATTCTTGAAGAC 
 TTACCAATGCTTAATCA 
1,075 19
blaVEB-1
VEB-FOR
VEB-REV
 CGACTTCCATTTCCCGATGC 
 GGACTCTGCAACAAATACGC 
642 19
blaSHV-1
SHV-FOR
SHV-REV
 TGGTTATGCGTTATATTCGCC 
 GCTTAGCGTTGCCAGTGCT 
867 20
blaGES-1
GES-1(F)
GES-1(R)
 ATGCGCTTCATTCACGCAC 
 CTATTTGTCCGTGCTCAGG 
864 21
blaIMP
IMP-A
IMB-B
 GAAGGCGTTTATGTTCATAC 
 GTACGTTTCAAGAGTGATGC 
587 22
blaVIM
VIM2004A
VIM2004B
 GTTTGGTCGCATATCGCAAC 
 AATGCGCAGCACCAGGATAG 
382 22
blaKPC
KPC (F)
KPC (R)
 ATGTCACTGTATCGCCGTCT 
 TTACTGCCCGTTGACGCCCA 
880 23
algD
algDF
algDR
 CGTCTGCCGCGAGATCGGCT- 
 GACCTCGACGGTCTTGCGGA 
313 24
lasB
lasBF
lasBR
 GGAATGAACGAAGCGTTCTCCGAC 
TTGGCGTCGACGAACACCTCG 
284 24
toxA
toxAF
toxAR
 CTGCGCGGGTCTATGTGCC 
 GATGCTGGACGGGTCGAG-3 
270 24
exoS 
exoS1-F
exoS1-R
 TCTGAATTCTTCCAGGCGGGTGAACATCA
TTTAGATCTCACCCTGGTATCCAAGGCGA
504 25
exoU
exoU-F
exoU-R
 GGG AAT ACT TTC CGG GAA GTT- 
 CGA TCT CGC TGC TAA TGT GTT- 
428 26
primers, sequences and their product size for de-
tection of extended-spectrum-β-lactamases (ESBLs), 
metallo-β-lactamases (MBLs) and virulence genes 
were used according to references as shown in Ta-
ble 2 [18-26].
Statistic
Data generated from the study were tabulated as 
Microsoft Excel sheet and uploaded to Statistical 
Package for Social Sciences (SPSS version 20). Iso-
lates from clinical sources were calculated for the 
categorical data by Fisher’s exact test, to deter-
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mine whether there are any statistical differences 
in comparison to type of antibiotic resistance and 
virulence factors. The level of significance was set 
at a p-value of 0.05 to test the hypothesis of no 
association; Fisher’s exact test is used for small 
sample size.
Results
A total of 70 P. aeruginosa isolates were included 
in this study, and these were recovered from 40 
wound swabs (57.1%), 27 urine samples (38.6%), 
and 3 pleural fluid samples (4.3%) of patients. 
Higher rate of isolates were recovered from males 
42(60%) than in females 28(40%). Antimicrobial 
susceptibility testing showed a high to low resis-
tance rates to azotreonam 49 (70%), followed by 
ceftazidime 32 (45.7%), ciprofloxacin 16 (22.9%), 
gentamicin 13 (18.6%), piperacillin-tazobactam 
11 (15.7%), amikacin 9 (12.9%), and imipenem 
6 (8.6%) respectively. All isolates were positive 
for potential genes of algD and lasB (100%), fo-
llowed by toxA (90%), exoS (34.3), exoU (24.3%) 
respectively. The rates of detected ESBL genes 
blaTEM,blaCTX-m, blaSHV-1,GES-1 , were 3.3%, 
6.6%, 10%, 3.3%, and 10% respectively. Howe-
ver, all isolates were negative for bla-KPC and bla-
VIM and IMP genes. The percentages of pigment 
production were 61.4% for pyocyanin, 37.1% for 
pyoverdin and 1.4% for pyorubin. (Tables 3, 4, 5 
& 6)
Discussion
This study included P. aeruginosa isolated from di-
fferent clinical specimens of patients whom were 
admitted for medical care at four major hospitals in 
Khartoum, Sudan. The majority of the isolates were 
recovered from wound swabs (57.1%), followed 
from urine (38.6%) and the least percentage was 
(4.3%) from pleural fluid. The study shows that all 
isolates have β-hemolytic activity and are mostly 
Table 3.  Antimicrobial susceptibility of 70 P. aerugi-
nosa isolates .
Antimicrobial agent 
Resistant Average
no %
Azotreonam 49 70 
Ceftazidime 33 47 
Ciprofloxacin 16 23
Gentamicin 13 19 
Piperacillin- tazobactam 11 16 
Amikacin 9 13 
Imipenem 6 09 
Table 5. Incidence of Virulence genes .
Among 70 P. aeruginosa 
isolates Gene
 P. aeruginosa isolates
no %
AlgD 70 100 
LasB 70 100 
ToxA 63 90 
exoS 24 34.3 
exoU 17 24.3 
Table 6.  Shows distribution of EBLs genes, plas-
mid-mediated virulence genes of KPC and 
VIM2/IMP.
GENE
 P. aeruginosa isolates
no %
blaTEM 1 3.3 
blaCTX-M 2 6.6 
blaSHV-1 3 10 
blaGES-1 1 3.3 
blaVEB 3 10 
KPC 0 0
VIM2/IMP 0 0
Table 4. MICs of 29 MDR isolates .
Domains/
Facets
MIC50 MIC90 
MIC 
Range 
Breakpoints 
for susceptible 
μg/ml μg/ml μg/ml) μg/ml* 
Amikacin 7.7 13.9 0.24- >256 ≤ 16
Ceftazidime 3.1 5.6 0.75- >256 ≤ 8 
Imipenem 2.3 4.1 0.38- >32 ≤ 2 
Ciprofloxacin 2.4 4.2 0.19- > 32 ≤ 1 
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producing pigmentation, either pyocyanin (61.4%) 
or pyoverdin (37.1%) and more rarely the pigment 
pyorubin (1.4%). 
Many studies have reported that most important 
virulence factors of P. aeruginosa are production 
of pigments, including mostly both pyoverdin and 
pyocyanin and blood hemolysis, which contribute 
to its pathogenicity during the infection process [27, 
28]. However, there are few studies comparing the 
incidence of pyocyanin and pyoverdin production of 
P. aeruginosa isolates according to their clinical sou-
rces. It has been demonstrated that pyocyanin has 
numerous antagonistic effects and damages host 
tissues in vitro and in vivo, including pro-inflamma-
tory and free radical effects [29]. 
Treatment of infections caused by P. aeruginosa 
has become challenging in recent years due to the 
ability of this pathogen to rapidly develop resistan-
ce to multiple classes of antibiotics. Therefore, the 
investigation of the genetics of antimicrobial resis-
tance of this organism may help to control and treat 
its infections by selection of useful antibiotics [30].
This study also showed high to low rates of re-
sistance markers to certain commonly used drugs 
in treatment of Pseudomonas infections including 
azotreonam (70%), ceftazidime (47%), ciprofloxacin 
(23%), gentamicin (19%), piperacillin-tazobactam 
(16%), amikacin (13%) and imipenem (9%) (Table 
3). A previous study conducted also in Sudan [31], 
reported that 
P. aeruginosa isolates from clinical samples of pa-
tients was 49.3%. The study showed that 74 of the 
isolates were resistant to carbenicillin [31]. While a 
new study conducted in Sudan found a multidrug-
resistant (MDR) P. aeruginosa isolate from urine of 
patient with a urinary tract infection was highly re-
sistant to many antibiotics including ciprofloxacin, 
gentamicin, ceftazidime, piperacillin, and merope-
nem [32].
The most important mechanisms of resistance 
to carbapenems are production of carbapenema-
se enzymes, which have the ability to hydrolyze 
penicillins, cephalosporins, monobactams and car-
bapenems. Carbapenem-resistant Klebsiella (KPC 
β-lactamases) hydrolyze most β-lactams, including 
carbapenems. [33, 34]. Therefore, early detection 
of this gene will help to avoid incorrect treatment, 
controlling hospital infections, and preventing the 
increase spread of resistant strains in hospital and 
community [35].
The study didn’t find any bla- VIM/IMP and KPC 
genes in P. aeruginosa isolates. Other mechanisms 
might be responsible for the resistance other than 
the KPC genes. It is interesting to note here that 
similar results to ours have been recently reported 
by a Jordanian study [2]. 
The study has demonstrated that all P. aerugi-
nosa isolates carried potential AlgD and lasB ge-
nes (100%), followed by other toxic genes (Table 
6). All MDR isolates were highly associated with 
these virulence genes compared to less resistant 
isolates. However, no significant associations were 
found between antibiotic resistance markers and 
putative virulence genes neither among MDR nor 
all P. aeruginosa isolates from urine or wound sam-
ples P. aeruginosa excreted many virulence factors 
and forms biofilms that contribute to its infection 
process. Virulence of P. aeruginosa is multifactorial, 
involving both secreted and cell-associated bacterial 
products such as elastase, alkaline protease, protea-
se IV, exotoxin A and exoenzymeS. However, most 
studies consider that exotoxin A, exoenzymeS and 
exoenzymeU are major virulence factors produced 
by most clinical P. aeruginosa strains, and the most 
toxic effects of these factors are causing host tissue 
damage [2, 36].
Conclusion
This study demonstrated high rates of antimicro-
bial resistance markers to most commonly used 
antibiotics in the treatment of P. aeruginosa infec-
tions. There was no significant relationship discove-
red between antimicrobial resistance markers and 
The InTernaTIonal arabIc Journal of anTImIcrobIal agenTs 
ISSN: 2174-9094
2020
Vol. 10 No. 1:2
doi: 10.3823/840
© Under License of Creative Commons Attribution 3.0 License 7
potential virulence genes among all P. aeruginosa 
isolates including MDR isolates from either urine or 
wound samples.
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